Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Exclusion Criteria

• •1. Patients who are known to be intolerant to capecitabine or allergic to any therapeutic drug, or who are participating in clinical studies of other new drugs;
• •2. Diseases that may interfere with oral medication treatment, including but not limited to swallowing difficulties, chronic diarrhea, or intestinal obstruction;
• •3. Previous or current history of other tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, and thyroid papillary carcinoma;
• •4. Sever heart disease;
• •5. Central nervous system metastasis with clinical symptoms;
• •6. Serious infections ;
• •7. Within 4 weeks of signing the informed consent form, receive systemic hormone or other immunosuppressive therapy with an equivalent dose greater than 10mg prednisone per day. Subjects with a systemic hormone dose ≤ 10mg prednisone per day or inhaled/topical corticosteroids can be enrolled in the study;
• •8. Patients with active chronic hepatitis B or active hepatitis C.
• •9. A history of interstitial pneumonia or other autoimmune diseases.
• •10. HIV infection;
• •11. Individuals with significant organ dysfunction or uncontrollable comorbidities, including but not limited to uncontrollable hypertension, decompensated liver cirrhosis, active peptic ulcer, or hemorrhagic disease;
• •12. Less than 6 weeks after major organ surgery;
• •13. Pregnant or breast feeding;
• •14. Patients with mental illness, those with a history of alcohol or drug abuse, or those who are unable to obtain informed consent;
• •15. Other researchers have determined that it is not suitable to participate in this trial.
• •16. Those who refuse or are unable to sign the informed consent form.